Harpoon Therapeutics Presents Interim Clinical Data from its

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , American , Roberth Uhl , , Exchange Commission , Harpoon Therapeutics Inc , American Society For Hematology , International Myeloma Working Group , Nasdaq , Harpoon Therapeutics , American Society , Annual Meeting , Activating Construct , Natalie Sacks , Chief Medical Officer , Dose Escalation , Dose Expansion Study , Patients With , Combination Therapeutics , Anti Tumor Activity , Webcast Details , Private Securities Litigation Reform Act , Harpoon Therapeutic ,